209960-91-8

Basic information

• Product Name: 2-methoxy-4-morpholinoaniline
• Synonyms: 2-methoxy-4-morpholinoaniline;2-methoxy-4-morpholinoaniline dihydrochloride;2-Methoxy-4-morpholin-4-yl-phenylamine;2-methoxy-4-(4-morpholinyl)Benzenamine;2-Methoxy-4-(morpholin-4-yl)aniline;2-Methoxy-4-morpholinobenzenamine
• CAS NO: 209960-91-8
• Molecular Formula: C₁₁H₁₆N₂O₂
• Molecular Weight: 208.259
• Mol File: 209960-91-8.mol
• Article Data: 22

Chemical Properties

• Melting Point: 78-80°
• Boiling Point: 408.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.163±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 6.30±0.40(Predicted)
• CAS DataBase Reference: 2-methoxy-4-morpholinoaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methoxy-4-morpholinoaniline(209960-91-8)
• EPA Substance Registry System: 2-methoxy-4-morpholinoaniline(209960-91-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 209960-91-8(Hazardous Substances Data)

Usage

Description

2-methoxy-4-morpholinoaniline, also known as Memantine, is a pharmaceutical drug with the molecular formula C12H17N2O. It is primarily used to treat moderate to severe Alzheimer's disease and dementia by regulating the activity of glutamate, a neurotransmitter implicated in these conditions.

Uses

Used in Pharmaceutical Industry:
Memantine is used as a therapeutic agent for the treatment of Alzheimer's disease and dementia. It functions by blocking the activity of N-methyl-D-aspartate (NMDA) receptors in the brain, which are involved in learning and memory processes. This action helps to mitigate the effects of excessive glutamate activity, a factor believed to contribute to the progression of Alzheimer's disease.
As an Alzheimer's Treatment:
Memantine is utilized as a neuroprotective agent to improve cognitive function and slow the progression of Alzheimer's disease in patients. It is available in various pharmaceutical forms, such as oral tablets, oral solutions, and extended-release capsules, and is administered under the guidance of healthcare professionals.
In managing side effects:
While Memantine can cause side effects like dizziness, headache, confusion, and constipation, its use is carefully directed by doctors to ensure patient safety and efficacy. The medication's dosing and administration are tailored to minimize these potential side effects while maximizing therapeutic benefits for patients with Alzheimer's disease and dementia.

Upstream product

• 6627-53-8 1-chloro-3-methoxy-4-nitrobenzene 
• 175135-19-0 AMA₅₆ 
• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 6950-88-5 4-(3-methoxy-4-nitro-phenyl)morpholine 

Downstream Products

• 1372263-46-1 N₄-benzyl-N₂-(2-methoxy-4-morpholinophenyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine 
• 1372262-89-9 N-(2-methoxy-4-morpholinophenyl)-4-(methylsulfonyl)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 1372262-90-2 N-ethyl-N-(3-((2-(2-methoxy-4-morpholinophenylamino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)methyl)pyridin-2-yl)methanesulfonamide 
• 1372262-84-4 N-ethyl-N-{3-[( {2-[(2-methoxy-4-morpholin-4-ylphenyl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)methyl]pyridin-2-yl}methanesulfonamide 
• 1372262-88-8 N-(2-methoxy-4-morpholinophenyl)-4-(methylthio)-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 700805-02-3 C₁₉H₂₀N₄O₃ 
• 700807-07-4 6-[5-amino-3-(2-methoxy-4-morpholin-4-yl-phenylamino)-[1,2,4]triazol-1-yl]-nicotinonitrile 
• 1254783-32-8 N-(3-(5-chloro-2-(2-methoxy-4-morpholinophenylamino)pyrimidin-4-yloxy)phenyl)acrylamide 

Relevant articles and documents

Optimization of WZ4003 as NUAK inhibitors against human colorectal cancer

NUAK, the member of AMPK (AMP-activated protein kinase) family of protein kinases, is phosphorylated and activated by the LKB1 (liver kinase B1) tumor suppressor protein kinase. Recent work has indicated that NUAK1 is a key component of the antioxidant stress response pathway, and the inhibition of NUAK1 will suppress the growth and survival of colorectal tumors. As a promising target for anticancer drugs, few inhibitors of NUAK were developed. With this goal in mind, based on NUAK inhibitor WZ4003, a series of derivatives has been synthesized and evaluated for anticancer activity. Compound 9q, a derivative of WZ4003 by removing a methoxy group, was found to be the most potential one with stronger inhibitory against NUAK1/2 enzyme activity, tumor cell proliferation and inducing apoptosis of tumor cells. By in vivo efficacy evaluations of colorectal SW480 xenografts, 9q suppresses tumor growth more effectively with an excellent safety profile in vivo and is therefore seen as a suitable candidate for further investigation.

COMPOUNDS AND THEIR USES AS MIF INHIBITORS

The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the i

A class of FLT3 kinase inhibitors, preparation and application thereof

The invention relates to a class of FLT3 kinase inhibitors, preparation and application thereof, wherein specifically the compound has a structure represented by a formula (I), and all groups and substituents are defined in the specification. The invention also discloses a preparation method of the compound, and application of the compound in inhibition of FLT3.